(1aS,5aS)-2-(2,4-difluorophenyl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid (tetrahydro-pyran-4-ylmethyl)amide | 1268878-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (1aS,5aS)-2-(2,4-difluorophenyl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid (tetrahydro-pyran-4-ylmethyl)amide
• 英文别名: (1aS,5aS)-2-(2,4-difluorophenyl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid (tetrahydropyran-4-ylmethyl)amide；(1aS,5aS)-2-(2,4-difluoro-phenyl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide；(2S,4S)-9-(2,4-difluorophenyl)-N-(oxan-4-ylmethyl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxamide
• CAS: 1268878-32-5
• 化学式: C₂₀H₂₁F₂N₃O₂
• 分子量: 373.402
• InChiKey: BIMFLDLUJSAALT-JSGCOSHPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氨甲基四氢吡喃 、 (1aS,5aS)-2-(2,4-difluoro-phenyl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 (1aS,5aS)-2-(2,4-difluorophenyl)-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid (tetrahydro-pyran-4-ylmethyl)amide
  参考文献：
  名称：

  [EN] CANNABINOID RECEPTOR MODULATORS
  [FR] MODULATEURS DES RÉCEPTEURS DE CANNABINOÏDES

  摘要：

  本发明涉及某些化合物Ia的配方和调节大麻素CB2受体活性的药物组合物。本发明还涉及某些化合物Ia的配方和药物组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和药物组合物用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎症性疼痛，神经痛，作为治疗的不良反应而发生的疼痛以及与骨关节炎相关的疼痛；痛觉过敏；触觉过敏；炎症性痛觉过敏；神经痛觉过敏；急性疼痛感；骨质疏松症；多发性硬化症相关的痉挛；自身免疫性疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活性和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩侧索硬化和帕金森病。

  公开号：

  WO2011025541A1

文献信息

• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20130165412A1

  公开（公告）日：2013-06-27

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，这些化合物调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，这些化合物调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛、肌肉疼痛、牙痛、偏头痛和其他头痛、炎性疼痛、神经痛、作为治疗副作用而发生的疼痛以及与骨关节炎相关的疼痛；高痛觉过敏；触发性痛觉异常；炎性高痛觉过敏；神经病性高痛觉过敏；急性疼痛；骨质疏松；多发性硬化症相关痉挛；自身免疫性疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活性和炎症；年龄相关性黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损害；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DE CANNABINOÏDES
  申请人：ARENA PHARM INC

  公开号：WO2011025541A1

  公开（公告）日：2011-03-03

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及某些化合物Ia的配方和调节大麻素CB2受体活性的药物组合物。本发明还涉及某些化合物Ia的配方和药物组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和药物组合物用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎症性疼痛，神经痛，作为治疗的不良反应而发生的疼痛以及与骨关节炎相关的疼痛；痛觉过敏；触觉过敏；炎症性痛觉过敏；神经痛觉过敏；急性疼痛感；骨质疏松症；多发性硬化症相关的痉挛；自身免疫性疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活性和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩侧索硬化和帕金森病。